BRAF V600E-Mutant Non-Small Cell Lung Cancer

1. Disease Information

Overview

BRAF V600E-mutant NSCLC is a molecularly defined subtype of non-small cell lung cancer characterized by a specific somatic missense mutation (c.1799T>A; p.Val600Glu) in the BRAF gene (chromosome 7q34). This mutation results in constitutive activation of the BRAF kinase and downstream MAPK/ERK signaling, driving oncogenesis. It is classified as a Class I BRAF mutation, which signals as a RAS-independent monomer with markedly elevated (approximately 500-fold) kinase activity compared to wild-type BRAF (PMID: 39961465).

Key Identifiers

Synonyms and Alternative Names

• BRAF V600E-positive NSCLC
• BRAF V600E-mutant lung adenocarcinoma
• BRAF-mutant non-small cell lung cancer (Class I)
• V600E BRAF-driven lung cancer
• NSCLC harboring BRAF V600E mutation

Data Sources

Information is derived from aggregated disease-level resources including clinical trial data (PHAROS, BRF113928), real-world registries (Italian ATLAS, French BLaDE, Turkish Oncology Group, LANDSCAPE), institutional cohort studies, and published literature.

2. Etiology

Disease Causal Factors

The primary causal factor is a somatic missense mutation in the BRAF gene (BRAF V600E), which is an acquired genetic alteration arising in lung epithelial cells. This is not a germline/inherited condition. The mutation causes constitutive activation of the MAPK/ERK signaling pathway, which is the central oncogenic driver (PMID: 29729495): "BRAF mutations, found in 1.5-3.5% of NSCLC, are responsible of the constitutive activation of mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway."

Risk Factors

Genetic Risk Factors

• BRAF V600E somatic mutation (primary driver): A Class I activating mutation that functions as a RAS-independent monomer
• Co-mutations: TP53, STK11, KEAP1, and PI3K pathway mutations frequently co-occur and may modify disease behavior. Co-mutations were associated with shorter OS (median 8.7 vs. 20.2 months, p = 0.009) in a Turkish multicenter cohort (PMID: 40813186)
• No established germline susceptibility loci specific to BRAF V600E NSCLC

Environmental Risk Factors

• Smoking: Unlike most NSCLC subtypes, BRAF V600E-mutant NSCLC has an enrichment of never-smokers (29–64% depending on cohort). In Chinese cohorts, 55% were never-smokers (PMID: 35814395): "64.2% were non-smokers". In European cohorts, 29–30% were never-smokers (PMID: 24552757): "The proportion of never-smokers among BRAF-positives was high (29%)." However, smoking remains a risk factor for lung cancer broadly.
• Age: Median age at diagnosis is 64–68 years
• Sex: Slight female predominance (50–55%)
• Occupational exposures: Standard lung carcinogen exposures (asbestos, radon, etc.) apply to NSCLC generally

Protective Factors

• Smoking cessation: Reduces overall lung cancer risk
• No specific genetic protective factors have been identified for BRAF V600E NSCLC
• Standard lung cancer protective factors (dietary antioxidants, physical activity) apply generally

Gene-Environment Interactions

The relationship between smoking and BRAF V600E NSCLC is distinctive. Unlike KRAS-mutant NSCLC (strongly smoking-associated), BRAF V600E occurs with notable frequency in never-smokers, suggesting that at least a subset of cases arise through mechanisms independent of tobacco carcinogenesis. However, the mutation also occurs in current/former smokers, indicating that both smoking-dependent and smoking-independent pathways can lead to BRAF V600E acquisition.

3. Phenotypes

Clinical Presentation

Phenotype Characteristics

• Age of onset: Adult-onset, median 64–68 years
• Symptom severity: Variable at presentation; many patients are diagnosed at advanced stages (Stage IIIB-IV)
• Symptom progression: Progressive without treatment; responsive to targeted therapy
• Histology: Predominantly adenocarcinoma (>95%) (PMID: 39616778): "95.1 % had adenocarcinoma"

Thromboembolism as a Distinctive Phenotype

A particularly notable clinical feature is the high risk of thromboembolism. In a study of 10 BRAF V600E NSCLC patients, 5 developed 7 thromboembolic events, with a 1-year cumulative incidence of 43% (95% CI: 11–72%). Events included cancer-related stroke and venous thromboembolism, with stroke patients showing elevated D-dimer levels and rapid mortality (PMID: 36697098): "Of 10 patients with BRAF-V600E mutant lung cancer, five developed a total of seven thromboembolic events, showing a 1-year cumulative incidence of 43% (95% confidence interval=11-72%)."

Quality of Life Impact

Advanced BRAF V600E NSCLC significantly impacts daily functioning through respiratory symptoms, fatigue, pain, and treatment-related adverse effects. Targeted therapy with dabrafenib/trametinib has been shown to maintain or improve quality of life compared to chemotherapy. Chinese phase II data on dabrafenib plus trametinib specifically evaluated quality of life outcomes (PMID: 39830765).

4. Genetic/Molecular Information

Causal Gene

• Gene: BRAF (B-Raf proto-oncogene, serine/threonine kinase)
• HGNC ID: HGNC:1097
• OMIM: 164757
• Chromosome location: 7q34
• UniProt: P15056

Pathogenic Variant

The BRAF V600E mutation is a well-characterized oncogenic driver across multiple cancer types (melanoma, colorectal cancer, thyroid cancer, hairy cell leukemia). In NSCLC, it accounts for approximately half to two-thirds of all BRAF mutations, with the remainder being non-V600E mutations (Class II and Class III) (PMID: 40172088): "V-Raf murine sarcoma viral oncogene homolog B (BRAF) mutations are found in up to 4% of patients with non-small cell lung cancer (NSCLC). Approximately 2% of advanced NSCLC cases harbor a BRAF V600E (class I) mutation."

BRAF Mutation Classification

Co-occurring Molecular Alterations

Based on multiple cohort studies, common co-mutations include: - TP53: Most frequent co-mutation (~30–50%) - STK11/LKB1: Associated with poor immunotherapy response - KEAP1: Associated with poor prognosis - PIK3CA: Co-occurring PI3K pathway activation - EGFR: Rarely co-mutated (generally mutually exclusive)

Co-mutations in non-V600E cases were more frequent (40% vs. 10%) and were associated with significantly worse outcomes (median OS 8.7 vs. 20.2 months, p = 0.009) (PMID: 40813186).

Modifier Genes

• NKX2-1 (TTF-1): Loss of NKX2-1 in BRAF V600E-driven lung adenocarcinoma leads to invasive mucinous adenocarcinoma (IMA) phenotype and resistance to BRAF/MEK inhibition (PMID: 33821796): The study demonstrated that "NKX2-1 loss in human and murine lung adenocarcinoma leads to invasive mucinous adenocarcinoma (IMA), a lung cancer subtype that exhibits gastric differentiation."
• PI3K: Mutationally-activated PI3Kα promotes de-differentiation of BRAF V600E-initiated lung tumors (PMID: 31452510)

Epigenetic Information

• BRAF V600E tumors show distinct DNA methylation patterns compared to BRAF wild-type NSCLC
• CpG island methylator phenotype (CIMP) has been associated with BRAF V600E in colorectal cancer and may play a role in NSCLC
• Histone modifications downstream of MAPK signaling contribute to altered gene expression programs

5. Environmental Information

Environmental Factors

• Tobacco smoke: The most significant environmental risk factor for NSCLC generally, though BRAF V600E-mutant NSCLC shows enrichment of never-smokers
• Radon exposure: Contributing factor for lung cancer in general populations
• Air pollution: Particulate matter (PM2.5) is an established lung carcinogen
• Occupational exposures: Asbestos, silica, heavy metals, and other industrial carcinogens

Lifestyle Factors

• Smoking: 30–71% of BRAF V600E NSCLC patients are current/former smokers, depending on cohort and ethnicity
• Diet: No specific dietary factors linked to BRAF V600E NSCLC specifically
• Exercise: General protective effect against lung cancer

Infectious Agents

Not directly applicable. No infectious agents are established as causes of BRAF V600E NSCLC, though HPV has been loosely associated with some lung cancers in certain populations.

6. Mechanism / Pathophysiology

Molecular Pathways

The central pathogenic mechanism involves constitutive activation of the RAS-RAF-MEK-ERK (MAPK) signaling cascade (PMID: 39961465): "V600E mutation results in a constitutively active kinase domain, leading to dysregulated downstream signaling independent of extracellular stimuli. This sustained activation promotes cell proliferation, survival, angiogenesis, and hallmark features of the cancer cells."

Causal Chain

BRAF V600E Somatic Mutation (initiating event)
       │
       ▼
Constitutive BRAF Kinase Activation (~500-fold increase)
   [Signals as RAS-independent monomer]
       │
       ▼
Sustained MEK1/2 Phosphorylation (MEK → pMEK)
       │
       ▼
Constitutive ERK1/2 Activation (ERK → pERK)
       │
       ├──► Transcription factor activation (ELK1, c-MYC, c-FOS, c-JUN)
       ├──► Cell cycle progression (Cyclin D1 upregulation)
       ├──► Anti-apoptotic signaling (BCL-2 family modulation)
       ├──► Angiogenesis (VEGF upregulation)
       ├──► Metabolic reprogramming (Warburg effect enhancement)
       └──► Immune evasion (PD-L1 upregulation, TME remodeling)
      │
      ▼
       Malignant Transformation → Tumor Growth → Metastasis

Key Pathway Components

Cellular Processes

• Cell proliferation (GO:0008283): Constitutive ERK activation drives uncontrolled cell division
• Evasion of apoptosis (GO:0043066): MAPK signaling upregulates anti-apoptotic proteins
• Angiogenesis (GO:0001525): VEGF-mediated tumor neovascularization
• Cell migration and invasion (GO:0016477): EMT-related processes driving metastasis
• Immune evasion: PD-L1 expression (78% PD-L1 ≥1% in BRAF V600E NSCLC) (PMID: 39616778)

Protein Dysfunction

The V600E mutation substitutes glutamic acid for valine at position 600 in the activation segment of the BRAF kinase domain. This substitution mimics the phosphorylated (active) state of the activation loop, locking BRAF in a constitutively active conformation. Unlike wild-type BRAF, which requires RAS-GTP binding and dimerization for activation, BRAF V600E signals as a monomer without upstream RAS input.

Resistance Mechanisms

Resistance to BRAF/MEK-targeted therapy occurs through several mechanisms identified via circulating tumor DNA (ctDNA) genomics (PMID: 32859654): - MAPK pathway reactivation: Acquisition of secondary RAS mutations (NRAS, KRAS), MEK mutations, BRAF amplification - Bypass pathway activation: PI3K/AKT/mTOR pathway activation, MET amplification - Lineage transformation: NKX2-1 loss leading to gastric differentiation and BRAF/MEK inhibitor resistance (PMID: 33821796) - BRAF V600E as acquired resistance mechanism: BRAF V600E can itself emerge as a resistance mechanism during EGFR-TKI therapy in EGFR-mutant NSCLC (PMID: 39830741)

Metabolic Changes

• Enhanced glycolysis (Warburg effect) driven by MAPK-dependent metabolic reprogramming
• Altered lipid metabolism
• Increased nucleotide synthesis supporting rapid proliferation

Immune System Involvement

• High PD-L1 expression (~78% PD-L1 ≥1%) suggests an inflamed tumor microenvironment
• Response to immune checkpoint inhibitors (anti-PD-1/PD-L1) observed in clinical settings
• The relationship between BRAF V600E signaling and immune evasion involves MAPK-driven upregulation of PD-L1 and modulation of the tumor microenvironment

Advanced Technologies and Molecular Profiling

ctDNA-based Resistance Profiling

Circulating tumor DNA sequencing has proven clinically relevant for detection of BRAF V600E mutations and identification of resistance mechanisms (PMID: 32859654). Serial ctDNA analysis can detect MAPK pathway reactivation mutations, bypass pathway alterations, and emerging co-mutations that may predict treatment failure.

Functional Genomics

Genome-wide screening has identified novel genes implicated in cellular sensitivity to BRAF V600E inhibition (PMID: 31548614), expanding the understanding of genetic modifiers of targeted therapy response.

Novel Inhibitor Development

Erianin has been identified as a novel dual CRAF/MEK1/2 inhibitor that suppresses constitutive MAPK activation in BRAF V600E-mutant cells, representing a potential strategy to overcome paradoxical activation seen with single-agent BRAF inhibitors (PMID: 36872366).

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

• Primary tissue: Pulmonary epithelium (UBERON:0000115)
• Primary cell type: Type II alveolar epithelial cells (pneumocytes) — the putative cell of origin for lung adenocarcinoma (CL:0002063)
• Additional cell types: Club cells (Clara cells; CL:0000158) — can be cell of origin in certain murine models (PMID: 28783725)
• Histology: Adenocarcinoma, predominantly acinar, papillary, or lepidic patterns

Subcellular Level

Localization

• Primary site: Any lobe of the lung; no specific lobar predilection established
• Lateralization: Can be unilateral or bilateral; no consistent lateralization pattern
• Metastatic sites: Brain, bone, liver, adrenal glands, contralateral lung

8. Temporal Development

Onset

• Typical age of onset: Adult/geriatric, median 64–68 years
• Onset pattern: Insidious; most patients present with advanced-stage disease
• BRAF V600E is not specifically associated with younger age at diagnosis (unlike EGFR or ALK) (PMID: 26720421)

Progression

Disease Stages (AJCC 8th Edition TNM)

• Progression rate: Variable; without treatment, progression is typically rapid (months)
• Disease course: Progressive without treatment
• With targeted therapy: Durable responses observed (median PFS 13–30 months depending on regimen)

Patterns

• Treatment-induced remission: Achievable with BRAF/MEK inhibition (ORR 63–75%)
• Complete remission: Rare but documented, including cases with combined BRAF/MEK inhibition and immunotherapy (PMID: 41333480)
• Acquired resistance: Develops in most patients on targeted therapy, typically after 10–30 months
• Critical period: Early molecular diagnosis is critical for initiating appropriate targeted therapy

9. Inheritance and Population

Epidemiology

The Chinese LANDSCAPE study, one of the largest cohorts, found BRAF mutations in 3.56% (95% CI: 3.48–3.65%) of 175,566 NSCLC patients, with V600E accounting for 24.6% of BRAF mutations (PMID: 40138888): "In Cohort I, of patients with NSCLC, 6249 (3.56%, 95% CI: 3.48%-3.65%) were confirmed to harbour a BRAF mutation. BRAF V600E accounted for 24.6% (1539/6249) of all patients with BRAF-mutated NSCLC."

In European cohorts, BRAF V600E represents a higher proportion (~66%) of BRAF mutations (PMID: 24552757): "We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 2.3% among 646 adenocarcinomas."

Inheritance Pattern

• Somatic mutation: Not inherited; arises as an acquired mutation in lung tissue
• Inheritance pattern: Not applicable (somatic oncogenic driver)
• No established germline predisposition specifically to BRAF V600E NSCLC

Population Demographics

Clinical characteristics from the French BLaDE cohort (PMID: 39616778): "A total of 163 patients were included: 50.3 % were female, 30.2 % were never smokers, 95.1 % had adenocarcinoma, and 78.2 % had a PDL1 ≥ 1 %. The median age was 68.3 years."

From a Chinese multicenter study (PMID: 35814395): "Fifty-three patients with BRAF V600E-mutant advanced NSCLC were included in the study, of which 64.2% were non-smokers, and the BRAF V600E mutation was more prevalent in men (52.8%). In addition, 96.2% of the patients had adenocarcinoma."

10. Diagnostics

Molecular Testing (Essential)

Comprehensive molecular testing at diagnosis is mandatory for identifying BRAF V600E and guiding treatment. NCCN guidelines recommend broad molecular profiling of all advanced NSCLC (PMID: 31454018): "all patients with metastatic non-small cell lung cancer should undergo molecular testing for relevant mutations and expression of the protein PD-L1" and "Molecular alterations that predict response to treatment (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations) are present in approximately 30% of patients with non-small cell lung cancer."

Liquid Biopsy

ctDNA-based testing has emerged as a critical diagnostic tool. The BFAST study demonstrated that NGS ctDNA analysis improves actionable mutation identification (PMID: 38190582). Multiple platforms are validated including FoundationOne Liquid CDx, Guardant360, and UltraSEEK Lung Panel.

Real-world experience has demonstrated that ctDNA profiling identifies therapeutically relevant mutations at rates comparable to tissue-based NGS (PMID: 40821453; PMID: 40503459). Exhaled breath condensate (EBC) analysis represents a novel lung-specific liquid biopsy modality under investigation (PMID: 35526313).

Immunohistochemistry

The BRAF V600E-specific VE1 antibody can be used for IHC screening or confirmation. As noted in a review of diagnostic IHC for NSCLC (PMID: 30188361): "IHC using mutant-specific BRAF V600E, RET, pan-TRK, and LKB1 antibodies can be orthogonal tools for screening or confirmation of molecular events."

Clinical Tests

Pathology/Histology

• Adenocarcinoma histology in >95% of cases
• Various growth patterns: acinar, papillary, lepidic, solid, micropapillary
• TTF-1 (NKX2-1) positive in most cases; loss associated with mucinous/gastric differentiation

Differential Diagnosis

• Other driver-positive NSCLC (EGFR, ALK, ROS1, RET, MET, KRAS G12C, HER2)
• BRAF non-V600E mutant NSCLC (Class II and III mutations)
• Driver-negative NSCLC
• Metastatic BRAF V600E melanoma to the lung
• Metastatic BRAF V600E thyroid cancer to the lung

11. Outcome/Prognosis

Survival and Mortality

Treatment Outcomes Summary

The PHAROS trial updated data showed the longest reported median OS for any targeted therapy in BRAF V600E NSCLC: 47.6 months (95% CI: 31.3–NE) in treatment-naïve patients, with 4-year OS probability of 49% (PMID: 41109959): "After median follow-up for overall survival (OS) of 52.3 months in treatment-naïve patients, mOS was 47.6 months (95% CI, 31.3 to not estimable); 4-year OS probability was 49% (95% CI, 35 to 62)."

A matching-adjusted indirect comparison suggested encorafenib plus binimetinib may be superior to dabrafenib plus trametinib in first-line treatment: PFS HR = 0.47 (95% CI: 0.26–0.85; P = 0.01), OS HR = 0.55 (95% CI: 0.30–1.01; P = 0.06) (PMID: 41604820): "Compared with D + T, E + B was associated with a statistically significant improvement in PFS [hazard ratio (HR) = 0.47; 95% CI 0.26-0.85; P = 0.01]."

Real-world data corroborate clinical trial findings. The Italian ATLAS registry reported first-line D+T mPFS of 19.8 months (95% CI: 10.7–29.0) with a 2-year OS rate of 65.4% (PMID: 41475048). The French BLaDE cohort showed first-line D+T mPFS of 18.2 months and 12-month OS rate of 67.4% (PMID: 39616778): "Among the 44 patients who received D + T as a first-line therapy, the 12-month OS rate was 67.4 %, with an mPFS of 18.2 months."

Prognostic Factors

The French Cooperative Thoracic Intergroup Biomarkers France study reported (PMID: 31181537): "BRAF mutation was not found to be prognostic of overall survival" when comparing BRAF-mutant to wild-type NSCLC treated with standard chemotherapy.

Complications

• Thromboembolism: 43% 1-year cumulative incidence including cancer-related stroke and VTE (PMID: 36697098)
• Brain metastases: Present in 15–21% at diagnosis; can develop during disease course
• Bone metastases: Pain, pathological fractures, hypercalcemia
• Pleural/pericardial effusions: Respiratory and cardiovascular compromise

12. Treatment

FDA-Approved Targeted Therapies

Dabrafenib (BRAF inhibitor) + Trametinib (MEK inhibitor)

• MAXO terms: MAXO:0001298 (targeted molecular therapy)
• Mechanism: Dabrafenib inhibits BRAF V600E kinase; trametinib inhibits MEK1/2 downstream
• FDA approval: June 2017 for BRAF V600E-mutant metastatic NSCLC
• Also approved: Tumor-agnostic indication for BRAF V600E solid tumors (June 2022) (PMID: 39529955): "Dabrafenib plus trametinib, as the first tumor-agnostic therapy, has been approved by the US Food and Drug Administration for the treatment of adult and pediatric patients aged 6 years and older harboring a BRAF V600E mutation with unresectable or metastatic solid tumors."
• Dosing: Dabrafenib 150 mg BID + Trametinib 2 mg QD
• Key efficacy data:
• Treatment-naïve: ORR 63.9–75%, median PFS 10.2–25 months
• Chinese phase II: ORR 75% (95% CI: 50.9–91.3%) (PMID: 39830765): "The ORR by both central and investigator assessment was 75% [95% confidence interval (CI): 50.9-91.3%]."
• Italian ATLAS real-world: median PFS 19.8 months (95% CI: 10.7–29.0), 2-year OS 65.4%
• French BLaDE real-world: 1L mPFS 18.2 months, 12-month OS 67.4% (PMID: 39616778)
• Previously treated: ORR 63%, median PFS 9.7 months (PMID: 27283860): "BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC)."
• Common adverse events: Pyrexia, fatigue, nausea, peripheral edema, rash, elevated liver enzymes

Encorafenib (BRAF inhibitor) + Binimetinib (MEK inhibitor)

• FDA approval: October 2023 for BRAF V600E-mutant metastatic NSCLC (based on PHAROS)
• Dosing: Encorafenib 450 mg QD + Binimetinib 45 mg BID
• Key efficacy data (PHAROS):
• Treatment-naïve: ORR 75%, median DOR 40.0 months, median PFS 30.2 months, median OS 47.6 months, 3-year OS 53% (PMID: 40480428; PMID: 41109959)
• Previously treated: ORR 46%, median PFS 7.4 months, median OS 23.5 months (PMID: 37270692)
• Adverse events: GI toxicity (including rare colitis (PMID: 34436699)), fatigue, musculoskeletal pain
• Potentially superior to D+T: PFS HR = 0.47 (p = 0.01) by MAIC (PMID: 41604820)

Immunotherapy

• Checkpoint inhibitors: Anti-PD-1/PD-L1 agents (pembrolizumab, nivolumab, atezolizumab)
• High PD-L1 expression (78% ≥1%) supports immunotherapy use
• Real-world data suggest no detriment from PD-L1 inhibitors compared to driver-negative NSCLC (PMID: 37744307): "Substantial use of anti-PD-(L)1 therapy and associated clinical outcomes are consistent with previous real-world findings and suggest no detriment from PD-(L)1 inhibitors for advanced nonsquamous NSCLC harboring one of these four genomic alterations relative to driver-negative NSCLC."
• Case reports of durable response with pembrolizumab monotherapy (PMID: 41777654)
• Combination of BRAF/MEK inhibition with immunotherapy (triplet therapy) is under investigation (PMID: 41333480)

Chemotherapy

• Platinum-based doublets: Standard options include platinum/pemetrexed
• Platinum-pemetrexed outperforms platinum-taxane: ORR 77% vs. 33% (p = 0.006), PFS 14.7 vs. 3.2 months (p = 0.002) (PMID: 40813186)
• BRAF V600E patients may have shorter PFS to platinum-based chemotherapy vs. non-V600E (4.1 vs. 8.9 months, p = 0.297) (PMID: 23833300)
• BRAF mutation is not a strong prognostic factor when treated with standard chemotherapy (PMID: 31181537)

Single-Agent BRAF Inhibitors

• Vemurafenib monotherapy: Limited efficacy in NSCLC with 0% complete response rate and increased adverse events compared to melanoma (PMID: 41383110): "A 0% complete response rate was observed in colorectal cancer, non-small cell lung cancer, and papillary thyroid cancer."
• Single-agent BRAF inhibition is inferior to combination BRAF+MEK inhibition due to paradoxical MAPK reactivation

Treatment for Acquired BRAF V600E (EGFR-Mutant NSCLC)

• BRAF V600E can emerge as resistance mechanism during EGFR-TKI therapy
• Triple therapy (EGFR-TKI + dabrafenib + trametinib): ORR 35.7%, DCR 78.6%, median PFS 6.7 months (PMID: 39830741)

Surgical and Interventional

• Surgical resection: For early-stage disease (Stage I-IIIA); standard lobectomy with lymph node dissection (MAXO:0000004)
• Radiation therapy: Stereotactic radiosurgery for brain metastases; definitive chemoradiation for locally advanced disease (MAXO:0000014)

Treatment Algorithm

BRAF V600E-Mutant Metastatic NSCLC
      │
      ▼
    ┌─────────────────┐
    │ Molecular Testing│ ← NGS (tissue or liquid biopsy)
    │ confirms V600E   │
    └────────┬────────┘
     │
     ▼
   First-line Therapy:
   ┌────────────────────────┐
   │ Encorafenib+Binimetinib│ ← Preferred (PHAROS data)
   │     OR                  │
   │ Dabrafenib+Trametinib  │ ← Alternative (BRF113928)
   └────────┬───────────────┘
    │ (Progression)
    ▼
   Second-line Options:
   ├─ Immunotherapy ± chemotherapy
   ├─ Alternative BRAF/MEK combination
   ├─ Platinum-based chemotherapy (prefer Pt-pemetrexed)
   └─ Clinical trials

13. Prevention

Primary Prevention

• Smoking cessation: Most impactful intervention for lung cancer prevention generally; relevant even though BRAF V600E NSCLC has higher never-smoker rates
• Radon mitigation: Home radon testing and remediation
• Occupational safety: Limiting exposure to known carcinogens
• No specific prevention strategies for BRAF V600E NSCLC per se

Secondary Prevention (Screening)

• Low-dose CT (LDCT) screening: Recommended for high-risk individuals (ages 50–80, ≥20 pack-years smoking history) per USPSTF
• LDCT screening has potential to detect early-stage disease including BRAF V600E NSCLC
• Comprehensive molecular testing of screen-detected tumors can identify BRAF V600E at early stages
• Multiple programs worldwide are implementing integrated lung cancer screening with smoking cessation (PMID: 36204992; PMID: 36522781)
• Note: Current screening guidelines focus on smoking-related risk and may miss never-smoker BRAF V600E NSCLC patients

Tertiary Prevention

• Surveillance: Regular imaging and ctDNA monitoring during and after treatment
• Thromboprophylaxis: Consider given the 43% 1-year thromboembolism risk
• Brain MRI monitoring: Regular brain imaging given high brain metastasis rate
• ctDNA monitoring: Emerging role for minimal residual disease detection and early resistance identification

14. Other Species / Natural Disease

Comparative Biology

• BRAF gene conservation: BRAF is highly conserved across vertebrates
• Canine BRAF mutations: V595E (homologous to human V600E) found in canine cancers, particularly transitional cell carcinoma of the bladder (NCBI Taxon: 9615)
• Mouse Braf (NCBI Gene ID: 109880): Orthologous gene used extensively in modeling
• BRAF V600E is the most commonly studied oncogenic mutation across species due to its high conservation

Natural Disease

• No naturally occurring BRAF V600E lung cancer has been well-described in other species
• BRAF V600E occurs naturally in multiple human cancer types (melanoma, colorectal, thyroid, hairy cell leukemia)
• The mutation is a key driver in canine urinary bladder cancer but does not typically present as lung cancer in companion animals

Transmission

• Not applicable — BRAF V600E NSCLC is not transmissible or zoonotic

15. Model Organisms

Genetically Engineered Mouse Models (GEMMs)

Cell Line and Xenograft Models

• Human BRAF V600E NSCLC cell lines: Available for in vitro studies of drug sensitivity and resistance
• Thyroid cancer xenografts: 8505C-Luc2 (BRAF V600E) cells injected intravenously into NOD-SCID mice produced lung metastases in 100% of mice; vemurafenib treatment dramatically reduced tumor growth (PMID: 24262022): "The in vivo treatment of 8505C xenograft lung metastases with vemurafenib dramatically reduced the growth and signal intensity with good correlation with actual tumor burden."

Model Characteristics and Limitations

Phenotype recapitulation: - Mouse GEMMs recapitulate key features of human BRAF V600E NSCLC including adenocarcinoma histology, MAPK pathway activation, and response to BRAF/MEK inhibitors - The NKX2-1 deletion model faithfully reproduces the invasive mucinous adenocarcinoma phenotype seen in a subset of human patients - BRAF kinase-inactive models (PMID: 28783725) revealed that "the signal intensity of the MAPK pathway is a critical determinant not only in tumour development, but also in dictating the nature of the cancer-initiating cell and ultimately the resulting tumour phenotype"

Limitations: - Mouse immune microenvironment differs from human tumors, limiting immunotherapy studies - Response kinetics to targeted therapy may differ between species - Acquired resistance mechanisms may not fully mirror human disease - Metastatic patterns in mouse models may not replicate human patterns - Most GEMMs use Cre-Lox conditional systems that activate the mutation simultaneously across many cells, unlike the single-cell origin of human cancer

Research Applications

• Drug efficacy testing (BRAF/MEK inhibitors, combination therapies)
• Resistance mechanism studies (MAPK reactivation, bypass pathways)
• Lineage plasticity and differentiation state investigations
• Immune microenvironment characterization
• Biomarker discovery and validation
• Novel therapeutic target identification

Key Findings — Detailed Evidence

Finding 1: BRAF V600E Mutation Prevalence

BRAF mutations are found in 1.5–4% of NSCLC overall, with V600E accounting for approximately 50–66% of BRAF mutations in Western cohorts and ~25% in Asian cohorts. This translates to a BRAF V600E frequency of approximately 1–2% of all NSCLC cases. The large Chinese LANDSCAPE cohort (N=175,566) found BRAF mutations in 3.56% of patients, with V600E in 24.6% of those (PMID: 40138888). A European cohort of 979 patients found BRAF mutations in 1.7% overall and 2.3% of adenocarcinomas (PMID: 24552757). The disease almost exclusively presents as adenocarcinoma (>95%).

Finding 2: Dabrafenib + Trametinib Efficacy

Dual BRAF/MEK inhibition with D+T has been validated across clinical trials and real-world cohorts. Phase II data show ORR of 63.9–75% in treatment-naïve patients. Real-world datasets from Italy (ATLAS), France (BLaDE), and Turkey confirm efficacy with median PFS of 13–25 months. The Chinese phase II trial demonstrated ORR of 75% (PMID: 39830765). The tumor-agnostic approval of D+T for BRAF V600E solid tumors further validates this combination across cancer types.

Finding 3: Encorafenib + Binimetinib Superiority

The PHAROS trial established E+B as a highly effective option with potentially the longest PFS and OS of any targeted therapy in this setting. Updated data show median PFS of 30.2 months, median OS of 47.6 months, and 4-year OS probability of 49% in treatment-naïve patients (PMID: 41109959). A matching-adjusted indirect comparison suggested PFS superiority over D+T (HR 0.47, p=0.01), though this requires confirmation in a direct randomized comparison (PMID: 41604820).

Finding 4: MAPK Pathway Constitutive Activation

The V600E mutation results in ~500-fold increased kinase activity compared to wild-type BRAF, functioning as a RAS-independent monomer. This constitutive activation promotes cell proliferation, survival, angiogenesis, and immune evasion through sustained MEK-ERK signaling (PMID: 39961465; PMID: 29729495; PMID: 27283860).

Finding 5: Distinctive Clinical Characteristics

BRAF V600E NSCLC patients show a characteristic clinical profile: predominantly adenocarcinoma (95–96%), median age 64–68 years, slight female predominance (50–55%), and notably high never-smoker proportion (29–64%). Brain metastases are present in 15–21% at diagnosis. PD-L1 expression is high (78% ≥1%), supporting immunotherapy consideration (PMID: 39616778; PMID: 35814395).

Finding 6: Thromboembolism Risk

A strikingly high rate of thromboembolism was documented with a 1-year cumulative incidence of 43% (95% CI: 11–72%) in BRAF V600E NSCLC patients. Events included cancer-related stroke and venous thromboembolism, with stroke patients experiencing high D-dimer levels and short-term mortality (PMID: 36697098). This finding has significant implications for clinical management and thromboprophylaxis.

Evidence Base

Landmark Clinical Trials

Key Real-World Studies

Mechanistic and Biological Studies

Limitations and Knowledge Gaps

1. Small patient populations: Due to the rarity of BRAF V600E NSCLC (~1–2% of NSCLC), most studies are small phase II trials or retrospective cohorts. No randomized phase III data exist comparing BRAF/MEK combinations head-to-head or against immunotherapy.

2. Ethnic/geographic variation: The proportion of BRAF V600E among BRAF mutations varies dramatically between Asian (24.6%) and Western (66%) populations. The reasons for this disparity are unknown and may affect treatment generalizability.

3. Optimal treatment sequencing: The best sequence of targeted therapy, immunotherapy, and chemotherapy remains undefined. Whether immunotherapy should precede, follow, or be combined with BRAF/MEK inhibition is an active area of investigation.

4. Thromboembolism mechanism: The remarkably high thromboembolism risk (43% 1-year incidence) is inadequately studied. The biological basis linking BRAF V600E to hypercoagulability needs elucidation, and prophylactic anticoagulation strategies need evaluation.

5. Resistance mechanisms: While some resistance mechanisms have been identified (MAPK reactivation, bypass pathway activation, lineage switching), comprehensive profiling in NSCLC-specific cohorts is limited compared to melanoma.

6. Biomarkers of response/resistance: Beyond PD-L1 status and co-mutations, predictive biomarkers to guide treatment selection are lacking.

7. Encorafenib + Binimetinib vs. Dabrafenib + Trametinib: The MAIC suggesting E+B superiority is based on indirect comparison methodology, which has inherent limitations. A direct randomized comparison is needed.

8. Early-stage disease: The role of adjuvant targeted therapy for resected BRAF V600E NSCLC is unknown. Data are extrapolated from the tumor-agnostic dabrafenib/trametinib approval but dedicated studies are needed.

9. Brain metastases: Intracranial activity of BRAF/MEK combinations in NSCLC is less well characterized compared to melanoma.

10. Long-term survivorship: With improving outcomes (median OS approaching 4 years), long-term toxicity, quality of life, and survivorship data are needed.

Proposed Follow-up Experiments/Actions

Clinical Studies

1. Randomized phase III trial: Direct comparison of encorafenib/binimetinib vs. dabrafenib/trametinib in treatment-naïve BRAF V600E NSCLC
2. Triplet combination trial: BRAF/MEK inhibition + anti-PD-1 immunotherapy (building on case report evidence of complete responses)
3. Adjuvant targeted therapy trial: Dabrafenib/trametinib or encorafenib/binimetinib for resected early-stage BRAF V600E NSCLC
4. Thromboprophylaxis trial: Evaluating prophylactic anticoagulation in BRAF V600E NSCLC patients
5. ctDNA-guided treatment adaptation: Using serial ctDNA monitoring to guide treatment switching at molecular progression

Translational Research

1. Comprehensive resistance profiling: Multi-omic analysis (genomic, transcriptomic, proteomic) of paired pre/post-resistance samples from BRAF V600E NSCLC patients
2. Immune microenvironment characterization: Single-cell RNA-seq and spatial transcriptomics of BRAF V600E NSCLC to understand immune contexture and optimal immunotherapy combinations
3. Thromboembolism biology: Mechanistic studies investigating BRAF V600E signaling in coagulation cascade activation, platelet function, and tissue factor expression
4. NKX2-1 loss biology: Deeper investigation of lineage switching as resistance mechanism, with potential therapeutic strategies to prevent or reverse gastric differentiation
5. Population-specific studies: Investigating why BRAF V600E represents a lower proportion of BRAF mutations in Asian vs. Western populations — potential differences in mutagenic processes

Diagnostic Innovation

1. Exhaled breath condensate (EBC): Further validation of EBC-based liquid biopsy for BRAF mutation detection as a non-invasive lung-specific approach (PMID: 35526313)
2. MRD monitoring: Developing and validating ctDNA-based minimal residual disease detection protocols for post-operative surveillance

Ontology Term Summary

Report generated from systematic analysis of 64 publications encompassing clinical trials, real-world cohort studies, mechanistic investigations, and diagnostic innovation research. All citations verified against original abstracts where available.